Journal article
The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol
Abstract
Background: The mineralocorticoid aldosterone may contribute to the risk of cardiovascular morbidity and mortality in patients receiving maintenance dialysis. Whether spironolactone, a mineralocorticoid receptor antagonist, improves outcomes for patients receiving maintenance dialysis is unclear.
Objective: To assess the efficacy and safety of spironolactone in patients receiving maintenance dialysis.
Authors
Walsh M; Collister D; Gallagher M; Mark PB; de Zoysa JR; Tyrwhitt J; Tennankore K; Sola L; Reis G; Xavier D
Journal
Canadian Journal of Kidney Health and Disease, Vol. 12, ,
Publisher
SAGE Publications
Publication Date
6 2025
DOI
10.1177/20543581251348187
ISSN
2054-3581